EW Edwards Lifesciences Corp

$EW ideal chart set up for short term swing. Acquired Dec 18th exp 95s calls. High probability of the stock retracung towards 92 in the next week or so. That alone would be a solid % gain on these contracts.

$EW: still held Edwards at the close on Oct 22, 2024? That later date matters too: the plan values those shares at purchase price minus $66.77, capped at $24.17. 33 days left, claim by Dec 2. Open Class Actions.

$EW: the Edwards plan puts $24.17 a share of alleged artificial inflation on July 25, 2024. That number drives the $39M settlement math. Bought Feb 6 to Jul 24, 2024? Claim by Dec 2. Open Class Actions.

$EW: held Edwards through the close on Jul 24, 2024? That holding rule decides the $39M settlement claim. Shares sold before that close get $0, and Edwards 401(k) plan shares do not count. Claim by Dec 2. Open Class Actions.

$EW good long term short as their TAVR program gets dismantled by innovation from competitors

$EW FDA approved the AUTUS size-adjustable valve, the first surgical pulmonary valve built specifically for pediatric congenital heart disease (company release, Oct 1). The design is the change. In kids, valve replacement is not a one-time event: children outgrow fixed valves and face repeat open-heart surgeries. AUTUS expands as the child grows through a minimally invasive transcatheter procedure. The proof ran inside the pivotal trial. When two patients saw valve performance deteriorate as they grew, both valves were expanded successfully without repeat surgery. 62 patients across 12 sites: no deaths, no strokes, no valve thrombosis requiring treatment, 100% free of device-related complications through 30 days. Materials first too: the leaflets are ePTFE polymer rather than animal-derived tissue, the first US valve approved that way. Closed Friday around 85.49, about 11% below the July 96.29 high. Street consensus: Moderate Buy, average target near 100.